# CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

Source: https://onco.cc/trials/nct06479356/  
OnCo record `nct06479356` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Relmacabtagene autoleucel in hodgkin lymphoma and non-hodgkin lymphoma, run by Shanghai Ming Ju Biotechnology Co., Ltd., now recruiting.

## Summary

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma is a phase 2 interventional study registered as NCT06479356 by Shanghai Ming Ju Biotechnology Co., Ltd., with 12 participants planned, started 2024-08-15 and due to reach its primary completion in 2025-04-30. Interventions recorded: Relma-cel. Conditions listed: Non-Hodgkin Lymphoma, Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06479356
- Phase: 2
- Setting: An Open-Label, Single-Arm Study of Relma-cel, CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for Relapsed or Refractory (R/R) LBCL
- Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd.
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT06479356: https://clinicaltrials.gov/study/NCT06479356

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Relmacabtagene autoleucel](https://onco.cc/drugs/relmacabtagene-autoleucel/)
- companies: [JW Therapeutics](https://onco.cc/companies/jw-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06479356.json